54527-84-3 Nicardipine HCl AKSci C652

Loading Please Wait...

C652 AKSci Reference Standard
Nicardipine HCl, 98% (HPLC)

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)methyl-2-[methyl(phenylmethyl)amino]-3,5-pyridinedicarboxylic acid ethyl ester hydrochloride

IDENTITY
CAS Number:	54527-84-3
MDL Number:	MFCD00057327
MF:	C26H30ClN3O6
MW:	515.99
EINECS:	259-198-4

SPECIFICATIONS & PROPERTIES
Purity:	98% (HPLC)
Spectra:	NMR, LCMS, FT-IR, HPLC
Physical Form:	Yellow powder
Melting Point:	179-187°C
Long-Term Storage:	Store at room temperature
UN #:	UN2811
Hazard Class:	6.1
Packing Group:	III

BIOLOGICAL INFO
Solubility:	MeOH; DMSO: ~1mg/mL
Application(s):	Calcium channel blockade
Form:	HCl salt

REVIEW
Nicardipine hydrochloride is a racemic, dihydropyridine calcium-channel blocker for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations.

REFERENCES

[1]	Murakami, Masuo; Takahashi, Kozo; Iwanami, Masaru; Fujimoto, Masaharu; Shibanuma, Tadao; Kawai, Ryutaro; Takenaka, Toichi Spasmolytic and vasodilatory 1,4-dihydro-4-phenyl-3,5-pyridinedicarboxylates Ger. Offen. (1974), DE 2407115 A1 19741010.
[2]	Iwanami, Masaru; Shibanuma, Tadao; Fujimoto, Masaharu; Kawai, Ryutaro; Tamazawa, Kazuharu; Takenaka, Toichi; Takahashi, Kozo; Murakami, Masuo Synthesis of new water-soluble dihydropyridine vasodilators Chemical & Pharmaceutical Bulletin (1979), 27(6), 1426-40.
[3]	Antoncic, Ljubo; Jazbec, Iztok; Kocjan, Darko; Krivec, Ivana Process for the preparation of 2-(benzylmethylamino)ethyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and its hydrochloride salt U.S. (1988), US 4769465 A 19880906.
[4]	Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987 Apr;33(4):296-345.